chest tightness
Recently Published Documents


TOTAL DOCUMENTS

161
(FIVE YEARS 103)

H-INDEX

9
(FIVE YEARS 4)

2022 ◽  
Author(s):  
Ying Zhang ◽  
Mengshu Cao ◽  
Xiaoqin Liu ◽  
Fanqing Meng ◽  
Xin Zhang ◽  
...  

Abstract Nodular fasciitis is a benign proliferation of myofibroblasts that usually arises in subcutaneous tissues of the trunk, neck, head, and upper extremities of young to middle-aged adults. It is not reported to arise in the intratracheal. We present a patient with chest tightness and asthma for three months. Chest computed tomography showed no displayed of left bronchus. The trachea of the left main bronchus was blocked by organisms under bronchoscope. The organisms were extracted and pathologically diagnosed as a rare, benign, intratracheal nodular fasciitis. One month later, the patient relapsed again and underwent resection.


2022 ◽  
Vol 50 (1) ◽  
pp. 030006052110728
Author(s):  
Ping Huang ◽  
Yuhong Li

Pulmonary embolism and splenic infarction are rare in patients with polycythemia vera. We herein describe a man in his early 60s whose main symptoms were chest tightness, cough, and sputum expectoration. Antibiotics, bronchodilators, and mucoactive agents did not improve his symptoms. Pulmonary artery computed tomography angiography showed pulmonary embolism, and abdominal computed tomography showed multiple hypodense foci in the spleen. Bone marrow aspiration cytology, biopsy, and genetic testing confirmed polycythemia vera. The patient’s symptoms were relieved after treatment with hydroxyurea and rivaroxaban. This case emphasizes that although pulmonary embolism and splenic infarction are relatively rare in patients with polycythemia vera, the possibility of polycythemia vera should be considered in clinical practice.


Author(s):  
Hyukmin Kweon ◽  
Jae-Won Choi ◽  
Seong-Yong Yoon

The development and distribution of vaccines and treatments as well as the use of disinfectants and hand sanitizers to cope with coronavirus disease 2019 (COVID-19) infection has increased rapidly. As the use of disinfectants and hand sanitizers increased, the number of unintended exposures to these substances also increased. A total of 8016 cases of toxic exposure to disinfectants and hand sanitizers were reported to the American Association of Poison Control Centers (AAPCC) from 1 January 2017 to 30 May 2021. The cases have been characterized by substance, sex, patient age, exposure reason and site, treatments received, and outcomes. The number of exposures correlates closely to the rise of COVID-19 cases, rising significantly in March 2020. About half of the total cases involved children less than 10 years old and 97% of those exposures per year were unintentional. In addition, the most common exposure site was the patient’s own residence. Over-exposure to disinfectants and hand sanitizers can cause symptoms such as burning and irritation of the eyes, nose, and throat, coughing, chest tightness, headache, choking, and, in severe cases, death.


2021 ◽  
Vol 50 (1) ◽  
pp. 131-131
Author(s):  
Ashley Gutierrez ◽  
Michael Gerbo ◽  
Samuel Treat ◽  
Nishant Sharma ◽  
Sean Jordan ◽  
...  
Keyword(s):  

2021 ◽  
Vol 11 (12) ◽  
pp. 91-95
Author(s):  
Archana Verma ◽  
Meenu Mishra ◽  
Raju Ninama

Background: Bronchial Asthma is a disease of airways that is characterized by hyper-responsiveness of the tracheobronchial tree to a variety of stimuli resulting in widespread spasmodic narrowing of the airway. According to WHO 2016, Asthma affects 235 million people worldwide, out of which 15-20 million people are from India. In India, the prevalence of self-reported asthma is 2% among women aged 15-49 years and 1% among young women aged 15-19 years as well as men aged 15-49 years as per the latest report. Prevalence of asthma is more in urban areas than rural area as due to smoke, pollution and environmental factor. In Ayurveda Bronchial Asthma has a high resemblance with Tamaka Shwasa which comes under Pranavaha Srotas. It is described in Brihatrayee as well as Laghutrayee. Acharya Charak and Sushruta has given detailed description of Tamaka Shwasa. Aim and Objectives: To study the effect of shwasa kuthar rasa in the management of (bronchial asthma) and to find out an effective Ayurvedic medicine for Tamaka Shwasa (Bronchial Asthma). Material and Methods: For this open clinical study, 10 patients of Tamak Shwasa (bronchial asthma) were registered from OPD of Kayachikitsa department and admitted in IPD of Pt. Khushilal Govt (Auto.) Ayurveda Hospital Bhopal. The patient was treated with Shwasa Kuthar Rasa. Duration of study was 30 days and follow up was done after completion of trial every week for 1 month, assessment was done on the basis of symptomatic relief and increase the range of FEV1 and FVC value after treatment. Observation: yielded symptomatic relief after treatment. The overall effect of the treatment in patient suggested that, there is 87.50 % relief in cough (Kasa), 90.01% relief in dyspnoea (Shwasakashta), 93.37% relief in chest tightness (Urashool) and 74.99% relief in wheezing (Ghurghurak) and value of FEV1 and FVC were increased up to 22.29% & 24.43% after treatment. Conclusion: On the basis of result obtained, it can be concluded that Shwasa Kuthar Rasa can be used as an effective medicine in the management of (Bronchial asthma). Key words: Tamaka Shwasa, Bronchial Asthma, Shwasa Kuthar Rasa.


Author(s):  
Shilen Shanghavi

Asthma is a chronic inflammatory lung condition characterised by variable respiratory symptoms (wheeze, shortness of breath, cough, and chest tightness) and variable expiratory airflow limitation, usually associated with airway inflammation. It affects 1-in-11 people in the UK and is the cause of over 75 000 hospital admissions per year. Given its prevalence, and the fact that patients are mainly cared for in the community, this article aims to highlight the need for a thorough annual asthma review and what that review entails. When carried out effectively, an asthma review will improve quality of life for those living with the condition, reduce their likelihood of hospital admission and reduce the cost to the NHS as a whole.


Author(s):  
Johanna Wong

Asthma is a common chronic condition, characterised by episodic acute exacerbations, which may require emergency treatment. According to Asthma UK, nationally 5 400 000 people are being treated for asthma; with life-threatening asthma attacks occurring every 10 seconds and three lives lost daily. In acute asthma, symptoms, including breathlessness, chest tightness, wheeze and cough, deteriorate progressively. Individuals with asthma symptoms often present to primary care and it is important that GPs can recognise and appropriately manage acute asthma. This article reviews the background, recognition and management of acute asthma in adults and children over the age of five, drawing on current guidelines.


2021 ◽  
Vol 5 (02) ◽  
pp. 73-76
Author(s):  
Salina Haque ◽  
Zulfia Zinat Chowdhury ◽  
Tamanna Bahar ◽  
A K M Mynul Islam ◽  
Mohammad Ali ◽  
...  

CML presenting with isolated extreme thrombocytosis is rare. We reported a 47 years old man who presented with history of right sided lower abdominal pain, vomiting, significant lethargy and chest tightness. Patient was mildly anaemic and abdominal examination revealed no organomegaly. On investigation, he was found to have extreme thrombocytosis (2050x109/L) and mild leucocytosis (31.7 x109/L) with mild anaemia. In view of extreme thrombocytosis, he was investigated for myeloproliferative disease especially essential thrombocythemia. He was found to be positive for BCR-ABL by reverse transcription PCR (RT-PCR) and negative for JAK2, CALR, MPL mutations. Ultimately, he was diagnosed as a case of CML with an atypical presentation. He received imatinib 400 mg/day and achieve complete haematological response at 15 days.


2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Ting Wang ◽  
Asmitananda Thakur ◽  
Baoqing Chen

Abstract Background Esophageal pleural fistula (EPF) is a rare but fatal complication associated with bevacizumab use; however, cases reports of EPF caused by bevacizumab have not been previously published. Case presentation A 66-year-old male patient diagnosed with stage IV lung adenocarcinoma on April 24, 2020 received 6 cycles of platinum-containing dual chemotherapy combined with bevacizumab followed by three cycles of bevacizumab monotherapy. Five days before admission, he experienced chest tightness, dyspnea, and right chest pain. Bed-side X-ray examination revealed a massive right hydrothorax, and food was found in the extracted pleural effusion. EPF was further confirmed by upper gastrointestinal radiography after oral administration of iohexol. The patient underwent jejunostomy as the distal esophagus could not be identified on gastroscopy, and eventually died of septic shock on January 16, 2021. Conclusions It is necessary to pay attention to EPF during bevacizumab use in patients with or without risk factors.


2021 ◽  
Vol 8 ◽  
Author(s):  
Lili Wu ◽  
Yongxin Wu ◽  
Haiyan Xiong ◽  
Biqi Mei ◽  
Tianhui You

Many patients who had coronavirus disease 2019 (COVID-19) had at least one symptom that persisted after recovery from the acute phase. Our purpose was to review the empirical evidence on symptom prevalence, complications, and management of patients with long COVID. We systematically reviewed the literature on the clinical manifestations of long COVID-19, defined by the persistence of symptoms beyond the acute phase of infection. Bibliographic searches in PubMed and Google Scholar were conducted to retrieve relevant studies on confirmed patients with long COVID that were published prior to August 30, 2021. The most common persistent symptoms were fatigue, cough, dyspnea, chest pains, chest tightness, joint pain, muscle pain, loss of taste or smell, hair loss, sleep difficulties, anxiety, and depression. Some of the less common persistent symptoms were skin rash, decreased appetite, sweating, inability to concentrate, and memory lapses. In addition to these general symptoms, some patients experienced dysfunctions of specific organs, mainly the lungs, heart, kidneys, and nervous system. A comprehensive understanding of the persistent clinical manifestations of COVID-19 can improve and facilitate patient management and referrals. Prompt rehabilitative care and targeted interventions of these patients may improve their recovery from physical, immune, and mental health symptoms.


Sign in / Sign up

Export Citation Format

Share Document